BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21365623)

  • 1. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy.
    Sonpavde G; Pond GR; Berry WR; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
    Cancer; 2011 Sep; 117(17):3963-71. PubMed ID: 21365623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
    Sonpavde G; Pond GR; Berry WR; de Wit R; Armstrong AJ; Eisenberger MA; Tannock IF
    Urol Oncol; 2012 Sep; 30(5):607-13. PubMed ID: 20888271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel.
    Sonpavde G; Pond GR; Templeton AJ; Fandi A; Tombal B; Rosenthal M; Armstrong AJ; Petrylak DP
    Eur Urol; 2016 Jun; 69(6):980-3. PubMed ID: 26497922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
    Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
    Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
    Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
    Armstrong AJ; Lin P; Higano CS; Iversen P; Sternberg CN; Tombal B; Phung D; Parli T; Krivoshik A; Beer TM
    Eur Urol Oncol; 2019 Nov; 2(6):677-684. PubMed ID: 31274110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
    Hussain M; Goldman B; Tangen C; Higano CS; Petrylak DP; Wilding G; Akdas AM; Small EJ; Donnelly BJ; Sundram SK; Burch PA; Dipaola RS; Crawford ED
    J Clin Oncol; 2009 May; 27(15):2450-6. PubMed ID: 19380444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
    Armstrong AJ; Tannock IF; de Wit R; George DJ; Eisenberger M; Halabi S
    Eur J Cancer; 2010 Feb; 46(3):517-25. PubMed ID: 20005697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
    Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
    Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
    Matsubara N; Chi KN; Özgüroğlu M; Rodriguez-Antolin A; Feyerabend S; Fein L; Alekseev BY; Sulur G; Protheroe A; Li S; Mundle S; De Porre P; Tran N; Fizazi K
    Eur Urol; 2020 Apr; 77(4):494-500. PubMed ID: 31843335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Qu YY; Dai B; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Ma CG; Yang WY
    Asian J Androl; 2013 Jan; 15(1):110-5. PubMed ID: 23147466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
    de Bono JS; Oudard S; Ozguroglu M; Hansen S; Machiels JP; Kocak I; Gravis G; Bodrogi I; Mackenzie MJ; Shen L; Roessner M; Gupta S; Sartor AO;
    Lancet; 2010 Oct; 376(9747):1147-54. PubMed ID: 20888992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characterization of Low Prostate-specific Antigen on Prognosis in Patients With Metastatic Castration-naive Prostate Cancer.
    Kodama H; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Narita T; Sato H; Mitsuzuka K; Tochigi T; Tsuchiya N; Arai Y; Habuchi T; Ohyama C
    Clin Genitourin Cancer; 2019 Dec; 17(6):e1091-e1098. PubMed ID: 31575477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
    Sonpavde G; Periman PO; Bernold D; Weckstein D; Fleming MT; Galsky MD; Berry WR; Zhan F; Boehm KA; Asmar L; Hutson TE
    Ann Oncol; 2010 Feb; 21(2):319-324. PubMed ID: 19633050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
    Rosenberg JE; Ryan CJ; Weinberg VK; Smith DC; Hussain M; Beer TM; Ryan CW; Mathew P; Pagliaro LC; Harzstark AL; Sharib J; Small EJ
    J Clin Oncol; 2009 Jun; 27(17):2772-8. PubMed ID: 19349545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.